Skip to main content

MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-17.76M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About INKT

MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of t...

IndustryBiological Products
IPO DatePending
CEOJennifer S. Buell, Ph.D.
Employees34
Stock ExchangeNASDAQ
Ticker SymbolINKT
Full Company Profile

Financial Performance

Financial Statements

News

MiNK Therapeutics IPO Registration Document (S-1)

MiNK Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC